BioPharma & Healthcare Related News

eGenesis Study Addressing Cross-Species Viral Transmission Concern in Xenotransplantation Published in Science

First Pigs without Active Porcine Endogenous Retrovirus (PERV) Produced Using CRISPR-Cas9 Genome Editing Technology – a Landmark Advance for Xenotransplantation Eliminating PERV Establishes a Foundation for Safe Xenotransplantation August 10, 2017 02:00 PM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--eGenesis, [...]

By | August 16th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Embryonic Editing Therapies Still Seem Unlikely Despite CRISPR Progress

After it was revealed in a pre-publication scoop three weeks ago by the MIT Technology Review, the news media has extensively covered a story about an Oregon research team’s use of the CRISPR gene editing technique to correct a disease-causing [...]

By | August 16th, 2017|BioPharma & Healthcare, News, Therapeutics|

Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research

SAN DIEGO, August 14, 2017 -- /PRNewswire/ -- Synthorx Inc., a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, announced today the appointment of Marcos Milla, Ph.D. as senior vice president of research. “Marcos is an [...]

By | August 15th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Oxford BioMedica announces a £2 million two-year collaboration co-funded by Innovate UK

The agreement is to explore a next generation gene and cell therapy manufacturing platform for clinical and commercial applications London, UK - 11 August 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy [...]

By | August 11th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Agilis Biotherapeutics and Gene Therapy Research Institution Enter into Strategic Partnership

Cambridge, MA, and Tokyo – August 2, 2017 -- Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution Co, Ltd. (GTRI), a [...]

By | August 5th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction

Location: Cambridge 01/08/2017 Genome sequence is based on Horizon’s Glutamine Synthetase (GS) Knock-Out CHO K1 manufacturing-ready cell line Sequenced in collaboration with the Wellcome Trust Sanger Institute, this high value reference tool, enables the industry to screen for genes associated with [...]

By | August 5th, 2017|BioPharma & Healthcare, News, Pharmaceuticals, Press Releases|